AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03585738 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inositol + Folic acid
Description: Daily oral supplementation before spontaneous conception until delivery:~Myo-Inositol: 1100 mg D-chiro-inositol: 27.6 mg Folic acid: 400 mcg
Study NCT03585738 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid
Description: Daily oral supplementation before spontaneous conception until delivery:~Folic acid: 400 mcg
Study NCT04670471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam is an intravenous anaesthetic and sedative drug. Remimazolam exhibits its anaesthetic effects via the benzodiazepine binding site at the GABAA receptor.
Study NCT04670471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil is a commonly used opioid in anaesthetic practice. It is a potent and fast-acting analgesic.
Study NCT05726708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-Learning
Description: On line modules of coaching for parents
Study NCT05726708 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: E-Learning
Description: On line modules of coaching for parents
Study NCT05330299 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMPASS
Description: Participants will be treated with an online CBT program that is specifically tailored to illness-related distress in the context of long-term conditions. It consists of 11 online modules and is therapist-supported.
Study NCT05391490 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: KCAT19 T cells
Description: Allogeneic, cord unit derived KCAT19 T cells
Study NCT03468140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Eculizumab will be given at a dose of 1200mg diluted in 0.9% sodium chloride (NaCl) to 5mg/mL for a total volume of 240 mL administered by IV infusion over 25-45 minutes in the anhepatic-phase during the transplant procedure, and a second dose of 900mg diluted in 0.9% NaCl to 5mg/mL for a total volume of 180 mL administered by IV infusion over 25-45 minutes will be given 24 hours following the first dose.
Study NCT03468140 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: Historical control arm
Study NCT06164002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: change in restoration material and margin design.
Description: comparing two different materials and two different designs. use artificial intelligence in the prediction of follow up results
Study NCT03879161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vu-Path™
Description: Femoral arterial access in eligible participants will be performed using the Vu-Path™.
Study NCT04502082 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ET140203 autologous T cell product
Description: Autologous T cells transduced with lentivirus encoding an ET140203 expression construct
Study NCT06202820 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CV Care Program
Description: Comprised of two, in-clinic, counseling sessions with oncology nurse practitioner or physician assistant for education on cardiovascular disease (CVD) and cardiovascular risk factors as well as recommendations for management.
Study NCT05169008 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular injection
Study NCT05169008 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)
Description: Nebulized inhalation through the mouth
Study NCT05019911 — intervention group
Intervention type: DEVICE
Intervention: Polysomnography
Description: In the cross-sectional part, the group of patients with COPD alone and the group of patients with COPD combined with sleep apnea hypopnea syndrome will be monitored by traditional sleep monitoring equipment (polysomnography) for vital signs in order to diagnose COPD combined with sleep apnea hypopnea syndrome.
Study NCT05019911 — intervention group
Intervention type: DEVICE
Intervention: Millimeter wave radar equipment
Description: In the cross-sectional part, the group of patients with COPD alone and the group of patients with COPD combined with sleep apnea hypopnea syndrome will be monitored by millimeter wave radar equipment for vital signs in order to diagnose COPD combined with sleep apnea hypopnea syndrome. In the cohort part, both groups of patients will be continuously monitored by millimeter wave radar equipment for vital signs for months in order to establish a model to predict acute exacerbations of COPD combined with sleep apnea hypopnea syndrome.
Study NCT05244252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmeditomidine and bupivacaine
Description: Transversus abdominis plane block will be given bilaterally
Study NCT05244252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: bupivacaine
Study NCT05147259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR011408 injection
Description: Drug: HR011408 injection (formulation A), administered subcutaneously. Drug: HR011408 injection (formulation B), administered subcutaneously.
Study NCT06313918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity training (HIT)
Description: Please see information already included in the arm descriptions.
Study NCT06313918 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High intensity training (HIT)
Description: Please see information already included in the arm descriptions.
Study NCT04995952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gross motor training
Description: Gross motor training activity (1 hour session, 3 times a week for 3 months). Pre ad post assessments will be taken. The Gross motor training activity will include: sit to stand, step-ups and walking. The sit to stand will be performed for 20 minutes involving 20 repetitions. We will progress from high seat sit to stand to low seat sit to stand. The step up will progress initially from a bench having low height to high height and then to stepping of stairs for 20 minutes involving 30 repetitions. The walking will occur from 3m walk and then increasing the distance
Study NCT04995952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trunk targeted training
Description: Trunk targeted training (1hour session, 3 times a week for 3 months). Pre and Post assessment will be evaluated. The trunk targeted training will include: weight supported treadmill walk, specific trunk exercises with vibration therapy and reaching forward to the limits of stability.~Specific trunk exercises will involve stride sitting to standing, sitting on a roll and moving the roll in diagonal and forward backward directions along with giving vibrational therapy on wobble board, side sitting. This activity will be performed for 30 minutes with 30 repetitions. Reaching forward to the limits of stability exercises will be performed. Asking the children to hold objects from right hand while reaching for an object on left side and vice versa. This will be performed for 20 minutes having 20 repetitions.
Study NCT04336878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Habits in Pregnancy and Beyond
Description: Habit-based intervention to support the development of 10 healthy dietary and activity behaviours for pregnant women with overweight or obesity.
Study NCT04837378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal Massage
Description: The massage starts from the left lower quadrant of the sigmoid colon. After the initial tension is removed, deep effloration, petrization and vibration maneuvers are started. Finally, the process is completed in about 15 minutes to cover the entire column.
Study NCT04837378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-bed Exercise
Description: In-bed exercises are passive exercises performed by caregivers when the patient is dependent on the bed, that is, when he cannot actively move on his own. These are movements applied to all joints of the upper and lower extremities and in all directions. Exercises are done in all directions on finger joints of both hands, wrists, elbow and shoulder joints, finger joints of both feet, ankles, knee and hip joints.
Study NCT04961411 — intervention group
Intervention type: PROCEDURE
Intervention: operation or non-operative treatment
Description: type of operation or if possible non-operative treatment
Study NCT05060601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gracey micro-curettes
Description: Mechanical debridement will be performed by means of ultrasonic scalers with specific thin tips and micro-curettes, in order to minimize trauma for gingival tissues.
Study NCT05060601 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Gracey curettes
Description: After local anaesthesia, non surgical subgingival debridement will be performed by standard Gracey curettes
Study NCT05440552 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Qualitative Fecal immunochemical test + APCS score
Description: Risk stratification using Qualitative Fecal immunochemical test and APCS score
Study NCT05440552 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative Fecal immunochemical test
Description: Use Quantitative Fecal immunochemical only for risk stratification
Study NCT05366062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERC1671
Description: ERC1671 is an autologous and allogeneic cells and lysates suspension generated from human glioblastoma (GBM) tumors harvested from patients undergoing surgery for glioblastoma. For each patient the treatment is composed of three allogeneic cells vaccine and lysates vaccine (ERC1671 A, B, C) plus from one autologous cells and lysate (ERC1671D).
Study NCT05366062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Sargramostim (Leukomax®, Leukine®); yeast-derived, recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF)
Study NCT05366062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is an alkylating agent, used for immunopotentiation. This drug is FDA approved and is being used off-label for the condition of hematopoietic stem cell transplant conditioning as an antineoplastic and immunosuppressant agent to modulate immunity.
Study NCT05366062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: A therapeutic antibody that binds to and blocks PD-1 located on lymphocytes. The receptor is generally responsible for preventing the immune system from attacking the body's own tissues - it is an immune checkpoint inhibitor.
Study NCT06519669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GT201 injection
Description: GT201 injection to treat Advanced lung cancer
Study NCT05569278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GE200486 0.5M Injection
Description: Single administration by intravenous (IV) hand injection without dilution, followed by a 5mL saline flush
Study NCT04911608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical spinal manipulation
Description: High-velocity, mid-range, low amplitude force at the segment of pain and/or segmental restriction. The participant will lay comfortably in a supine position, the practitioner will then use his clinical discretion to select the most appropriate or symptomatic cervical motion segments and attempt to localize the manual thrust at those levels. A maximum of 2 attempts for each side of the cervical spine will be allowed regardless of the having achieved joint cavitation.
Study NCT04911608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical spinal mobilization
Description: Participant will lay comfortably in a prone position, the practitioner will then use his clinical discretion to select the most appropriate or symptomatic cervical motion segments and attempt to localize the manual forces at those segments.
Study NCT05317741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IA-14069
Description: Subjects received IA-14069 tablet orally on Day 1.
Study NCT05317741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects received matching placebo tablet orally on Day 1.
Study NCT05283772 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Development of eye tracker for simulation training in nursing
Description: Purpose: To develop a cost-effective and effective eye tracker for simulation training in nursing in Turkey.~The wearable eye tracker consists of a front camera that will detect the pupil and determine the gaze region of the eye, and glasses or an alternative headband to which these cameras will be connected. A portable mini-computer will be used to process the obtained images. While recording and monitoring the eye movement with the pupil detection camera, real-world images in the user's field of view will be recorded by the front camera and the focal points will be determined. By establishing a linear connection between these found points, temperature (heat) maps will be created at the points where the eye looks.
Study NCT06310941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation
Description: Combined use of mechanical insufflation-exsufflation with nebulized hypertonic saline in intubated patients with nosocomial respiratory tract infection
Study NCT06310941 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: systemic antibiotic therapy and catheter suctioning of secretions as recommended by guidelines
Study NCT06310941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic saline with hyaluronic acid
Description: Commercially available combination of 7% hypertonic saline with 0.1% hyaluronic acid given as nebulization during the MI-E session
Study NCT06044077 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: 23-valent pneumococcal polysaccharide vaccine from Aimei Vacin BioPharm (Zhejiang) Co., Ltd.
Study NCT06044077 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: control pneumococcal polysaccharide vaccine
Description: 23-valent pneumococcal polysaccharide vaccine from Merck Sharp \& Dohme Corp
Study NCT06214234 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Band ligation
Description: Band ligation in variceal bleeding
Study NCT04609670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-ALXN2050
Description: A single dose of 200 milligrams (\~85 microcuries) \[14C\]-ALXN2050 will be administered orally.
Study NCT06521905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intravascular lithotripsy
Description: The intravascular lithotripsy can intermittently release acoustic pressure waves at the site of vascular calcification lesions, thereby achieving the goal of rupturing calcified plaques; After the rupture of calcified plaques, the vascular calcification lesions can be fully dilated with the help of lower balloon inflation pressure.
Study NCT06521905 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-pressure ballon
Description: High pressure balloon dilation, as the main method for traditional treatment of insufficient stent expansion caused by calcification, has a good therapeutic effect on insufficient stent expansion caused by calcification
Study NCT04703075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine 600 mg and INH 300 mg
Description: Participants will receive Rifapentine 600 mg and INH 300 mg
Study NCT04703075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifapentine 900 mg and INH 900 mg
Description: Participants will receive Rifapentine 900 mg and INH 900mg
Study NCT05226637 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESWT (extra-corporeal shock wave therapy)
Description: The ESWT device (Storz Medical Duolith SD1),
Study NCT05226637 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham : The ESWT device (Storz Medical Duolith SD1),
Description: In doing so, the sham head still actuates and makes the same sounds but produces no shockwave. Because the patients receiving this intervention are naïve to ESWT, they will not be biased by the sensation it produces. Communication during treatment will be limited to avoid inadvertent bias.
Study NCT05291312 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Adenoidectomy with endoscopic assisted coblation (EACA) and Adenoidectomy with conventional curettage (CCA)
Description: IN the (EACA) group slight head flexion position will be given to the patients and Boyle-Davis retractor will be placed to keep the mouth open. The soft palate will be elevated upward by inserting a plastic feeding catheter.. IN the (CCA) group, by orotracheal intubation , Boyle-Davis mouth retractor will be used to provide mouth opening
Study NCT06005064 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill oil
Description: Superba krill oil
Study NCT06005064 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vegetable oil
Description: Mixed vegetable oil
Study NCT04652037 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acrysof IQ Vivity Toric Extended Vision Intraocular Lens Implantation
Description: Implantation during bilateral cataract surgery of a new non-diffractive extended vision presbyopia and astigmatism correcting intraocular lens (Acrysof IQ Vivity Toric Extended Vision Intraocular Lens)
Study NCT06654531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Under a sterile technique, spinal anesthesia will be carried out using a 22-G Quincke spinal needle after skin infiltration with 2% lidocaine 3 ml a t the L3-L4 level, a midline approach in the sitting position, and then in the supine position.~Th e time of spinal injection will be considered time zero (T0). The I.V drug regimen will be started according to the group to which patients will be assigned.patients will receive intrathecal 15 mg hyperbaric bupivacaine together with 5 μg Dexmedetomidine in group 2
Study NCT06595719 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-Strain Probiotics
Description: Each sachet of the multi-strain probiotics contain 30 billion CFU of 6 strains which includes Lactobacillus acidophilus BCMC®12130, Lactobacillus casei subsp BCMC®12313, Lactobacillus lactis BCMC®12451, Bifidobacterium bifidum BCMC®02290, Bifidobacterium infantis BCMC®02129, Bifidobacterium longum BCMC®02120
Study NCT06595719 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Replicate for multi-strain probiotics without any active ingredients
Study NCT06378216 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: neurocognitive evaluations
Description: clinical and neurocognitive evaluations neuroradiological evaluation through cerebral magnetic resonance
Study NCT06015152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.045% Topical Application Lotion [ARAZLO]
Description: \[ARAZLO\]
Study NCT05932667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan
Description: The study treatment, including a combination of milademetan and fulvestrant, is administered into two successive parts: a safety run-in part followed by a phase II part. Once GATA3 mutational status confirmed, patients will continue to receive study drug treatment until progression of disease, unacceptable toxicity, patient withdrawal of consent, Investigator decision, lost to follow-up, death, patient non-compliance, or study termination by Sponsor.
Study NCT05932667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Reported Outcomes (PROs) and Health-Related Quality of Life (HRQOL)
Description: Measure of interest is the mean difference in the change from baseline to different specific visit (each disease radiological assessment, disease progression and/or treatment discontinuation) in total/subscale scores of the 5 Dimension 5 Level (EQ-5D-5L) scale and the EORTC-QLQ-C30 questionnaire
Study NCT04922567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25mg po on day 1-10
Study NCT04922567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 750mg/m² iv on day1
Study NCT04922567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750mg/m² iv on day1
Study NCT04922567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 50mg/m² iv on day 1
Study NCT04922567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50mg/m² iv on day 1
Study NCT04922567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 1.4mg/m² iv on day 1
Study NCT04922567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4mg/m² iv on day 1
Study NCT04922567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 100mg po on day1-5
Study NCT04922567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100mg po on day1-5
Study NCT06165289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRP Injection
Description: Endoscopic balloon dilatation combined with autologous platelet-rich plasma (PRP) injection with different concerntrations